Aug. 31 at 7:13 PM
Mizuho⬆️
$BBIO's PT,⬆️US Peak Sales Estimates and said -- BBIO (OP, increasing PT to
$110): Story continues to move forward with four potential commercial products by 2H27; Commercial Day 10/8 (potential catalyst).
$IONS -
$AZN ALNY PFE
Mizuho added—We increase our PT to
$110 (from
$96) on higher Attruby numbers, post IONS/AZN's (both NC) CARDIO-TTRansform failure.
We currently model Attruby at ~
$4BN peak sales in the US (up from ~
$3.4BN), and even this may prove conservative.
Recall, BBIO's Commercial Day is on 10/8.
One potential scenario, we believe (to be clear, management has not guided to it), may be updated ATTR-CM market share work, as recall, BBIO's prior work showing potentially 30-40% peak share and an implied
$4BN US sales estimate for Attruby was all done prior to CARDIO-TTRansform failing.
